CD274 and neoplasm: Currently, PD-L1 expression on tumor cells assessed by immunohistochemistry is the only approved diagnostic biomarker for immunotherapy in patients with NSCLC and has been convincingly demonstrated to be associated with the efficacy of ICIs in NSCLC 9,10.